Back to Search
Start Over
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
- Source :
- Breast Cancer Research : BCR, Breast Cancer Research, Vol 20, Iss 1, Pp 1-17 (2018)
- Publication Year :
- 2018
- Publisher :
- BioMed Central, 2018.
-
Abstract
- Background Estrogen promotes breast cancer development and progression mainly through estrogen receptor (ER). However, blockage of estrogen production or action prevents development of and suppresses progression of ER-negative breast cancers. How estrogen promotes ER-negative breast cancer development and progression is poorly understood. We previously discovered that deletion of cell cycle inhibitors p16Ink4a (p16) or p18Ink4c (p18) is required for development of Brca1-deficient basal-like mammary tumors, and that mice lacking p18 develop luminal-type mammary tumors. Methods A genetic model system with three mouse strains, one that develops ER-positive mammary tumors (p18 single deletion) and the others that develop ER-negative tumors (p16;Brca1 and p18;Brca1 compound deletion), human BRCA1 mutant breast cancer patient-derived xenografts, and human BRCA1-deficient and BRCA1-proficient breast cancer cells were used to determine the role of estrogen in activating epithelial-mesenchymal transition (EMT), stimulating cell proliferation, and promoting ER-negative mammary tumor initiation and metastasis. Results Estrogen stimulated the proliferation and tumor-initiating potential of both ER-positive Brca1-proficient and ER-negative Brca1-deficient tumor cells. Estrogen activated EMT in a subset of Brca1-deficient mammary tumor cells that maintained epithelial features, and enhanced the number of cancer stem cells, promoting tumor progression and metastasis. Estrogen activated EMT independent of ER in Brca1-deficient, but not Brca1-proficient, tumor cells. Estrogen activated the AKT pathway in BRCA1-deficient tumor cells independent of ER, and pharmaceutical inhibition of AKT activity suppressed EMT and cell proliferation preventing BRCA1 deficient tumor progression. Conclusions This study reveals for the first time that estrogen promotes BRCA1-deficient tumor initiation and progression by stimulation of cell proliferation and activation of EMT, which are dependent on AKT activation and independent of ER. Electronic supplementary material The online version of this article (10.1186/s13058-018-0996-9) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
Epithelial-Mesenchymal Transition
endocrine system diseases
medicine.drug_class
Estrogen receptor
Breast Neoplasms
Mammary Neoplasms, Animal
Tumor initiation
lcsh:RC254-282
Metastasis
03 medical and health sciences
Mice
0302 clinical medicine
Cancer stem cell
Medicine
Animals
Cyclin-Dependent Kinase Inhibitor p18
Humans
Breast
skin and connective tissue diseases
PI3K/AKT/mTOR pathway
Cyclin-Dependent Kinase Inhibitor p16
Cell Proliferation
Mammary tumor
business.industry
Cancer stem cells
BRCA1 Protein
EMT
Estrogens
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
BRCA1
Estrogen
Xenograft Model Antitumor Assays
030104 developmental biology
Cell Transformation, Neoplastic
Receptors, Estrogen
Tumor progression
030220 oncology & carcinogenesis
Cancer research
Neoplastic Stem Cells
Female
business
Research Article
Subjects
Details
- Language :
- English
- ISSN :
- 1465542X and 14655411
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Breast Cancer Research : BCR
- Accession number :
- edsair.doi.dedup.....5edc6f09f595878782b614a460dc4125